University of Minnesota Blood and Marrow Transplant Program - Pediatrics
Welcome,         Profile    Billing    Logout  
 5 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ebens, Christen
NCT03367546: Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases

Terminated
2
5
US
Blood and Marrow Transplant
Masonic Cancer Center, University of Minnesota
Sickle Cell Disease, Thalassemia, High Risk Hematologic Disorders, Cerebral Adrenoleukodystrophy, Inherited Metabolic Disorders
12/22
12/22
NCT06412497: MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Recruiting
2
60
US
Rituximab, Rabbit ATG, Thymoglobulin, Cyclophosphamide, Fludarabine, Total Body Irradiation, TBI, Cell Infusion, Post-Transplant G-CSF, Filgrastim, Tacrolimus, Mycophenolate Mofetil, MMF
Masonic Cancer Center, University of Minnesota
Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria
05/35
05/36
NCT00357565: Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia

Active, not recruiting
2
33
US
filgrastim, G-CSF, busulfan, Busulfex, cyclosporine, CSA, fludarabine phosphate, Fludara, melphalan, Alkeran, mycophenolate mofetil, MMF, umbilical cord blood transplantation
Masonic Cancer Center, University of Minnesota
Leukemia, Myelodysplastic Syndromes, Childhood Acute Myeloid Leukemia in Remission, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Previously Treated Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess Blasts, Refractory Anemia, De Novo Myelodysplastic Syndrome, Childhood Myelodysplastic Syndrome
06/24
12/25
CSIDE, NCT03619551: Conditioning SCID Infants Diagnosed Early

Recruiting
2
64
Canada, US
Busulfan, Cell processing for TCRαβ+/CD19+ depletion, CliniMACS
Michael Pulsipher, MD
SCID
08/26
08/26
NCT02963064: JSP191 Antibody Targeting Conditioning in SCID Patients

Recruiting
1/2
40
US
Humanized anti-CD117 Monoclonal Antibody (JSP191)
Jasper Therapeutics, Inc.
SCID
06/25
06/28
NCT02670837: Study of Cellutome System for Treatment of Individual Lesions in EB Pts

Completed
N/A
34
US
Cellutome Epidermal Harvesting System
Masonic Cancer Center, University of Minnesota
Epidermolysis Bullosa
03/23
04/24
NCT01652092: Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Recruiting
N/A
30
US
Alemtuzumab 0.3 mg, Campath-1H, Cyclophosphamide, Cytoxan, Busulfan, Myerlan, Stem Cell Transplantation, Fludarabine phosphate 40 mg, Fludara, Melphalan, Alkeran, Alemtuzumab 0.2 mg, Campath 1-H, Fludarabine phosphate 30 mg, MESNA, mercaptoethane sulfonate Na (Na being the symbol for sodium), Mesnex
Masonic Cancer Center, University of Minnesota
SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome, Bare Lymphocyte Syndrome, Common Variable Immunodeficiency, Chronic Granulomatous Disease, CD40 Ligand Deficiency, Hyper IgM Syndrome, X-linked Lymphoproliferative Disease, Hemophagocytic Lymphohistiocytosis, Griscelli Syndrome, Chediak-Higashi Syndrome, Langerhan's Cell Histiocytosis
12/25
12/26

Download Options